BUSINESS

Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion

PUBLISHED Sep 20, 2026, 7:25 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 23

Center 100%

Sources: 23

Australia-based Telix Pharmaceuticals has agreed to acquire Germany-headquartered ITM Isotope Technologies Munich SE for approximately $1.65 billion on a cash- and debt-free basis. Under the transaction terms, ITM shareholders are expected to receive roughly $1.25 billion paid in Telix ordinary shares priced at $11.84 per share, subject to closing adjustments. Telix specializes in molecularly targeted radiation for cancer diagnostic imaging and therapy, while ITM manufactures medical radioisotopes and targeted radiopharmaceuticals. The acquisition aims to vertically integrate radiopharmaceutical manufacturing supply chains, combining Telix’s clinical distribution network with ITM’s isotope production infrastructure. Regulatory filings, anti-trust reviews, and shareholder votes remain pending. Neither company has disclosed exact closing timelines or break-fee provisions. The transaction follows prior strategic supply agreements established between the two radiopharmaceutical entities. Industry analysts note the deal reflects ongoing consolidation within global nuclear medicine markets driven by rising demand for targeted precision oncology therapies. Operations at both firms continue independently pending final transaction clearance.

By Yusra M. | JQJO News

Timeline of Events

On March 18, 2021, Telix and ITM extended global non-exclusive supply agreements.
On April 9, 2024, Telix finalized the acquisition of commercial-stage IsoTherapeutics.
On March 5, 2024, Telix announced the acquisition of Canadian isotope producer ARTMS.
On August 20, 2026, Telix reported half-year financial results highlighting pipeline momentum.
On September 14, 2026, U.S. FDA approved Telix brain cancer imaging agent Pixclara.
On September 21, 2026, Telix announced agreement to acquire ITM for $1.65 billion.
On coming weeks, regulatory filings and antitrust submissions will be processed across jurisdictions.
In coming months, shareholder meetings will vote on the proposed $1.65 billion transaction.
In coming quarters, integration planning for manufacturing and clinical supply chains will proceed.
By mid-2027, transaction closing is anticipated subject to regulatory approvals and closing conditions.

News Intelligence

Immediate US impact: Secures long-term medical isotope supply for clinical oncology trials.
Possible long-term US impact: Expands localized precision radiopharmaceutical treatment availability for cancer patients.
Reader priority: Track regulatory filings and clinical trial milestone updates from Telix.
Most Affected: U.S. oncology patients, nuclear pharmacies, and diagnostic imaging centers nationwide.

Media Bias

Articles Published:: 23
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 23

Explain Framing

Left: Insufficient evidence available to establish distinct left-leaning systemic political framing for this transaction. Center: Emphasizes corporate valuation figures, share consideration mechanics, and supply chain vertical integration. Right: Insufficient evidence available to establish distinct right-leaning systemic political framing for this transaction.